Multivariate analysis on overall survival
| Prognostic factor . | Parameter estimate . | SE . | Hazard ratio . | 95% CI of hazard ratio . | P . |
|---|---|---|---|---|---|
| Treatment group: tipifarnib vs BSC | 0.049 | 0.114 | 1.050 | (0.84-1.314) | .667 |
| Age: ≥ 75 vs < 75 | 0.252 | 0.116 | 1.287 | (1.025-1.616) | .030 |
| ECOG: 2 vs 0 and 1 | 0.832 | 0.131 | 2.298 | (1.778-2.97) | .000 |
| Unfavorable cytogenetics: yes vs no | 0.564 | 0.120 | 1.758 | (1.39-2.223) | .000 |
| AML with myelodysplasia vs AML without myelodysplasia | −0.089 | 0.124 | 0.915 | (0.718-1.166) | .473 |
| LDH U/L: > 1500 vs ≤ 1500 | 0.081 | 0.271 | 1.085 | (0.638-1.845) | .764 |
| WBC count: > 25 giga/L vs ≤ 25 giga/L | 0.214 | 0.172 | 1.239 | (0.884-1.736) | .213 |
| Bone marrow blasts: > 50% vs ≤ 50% | 0.542 | 0.124 | 1.719 | (1.347-2.194) | .000 |
| Prognostic factor . | Parameter estimate . | SE . | Hazard ratio . | 95% CI of hazard ratio . | P . |
|---|---|---|---|---|---|
| Treatment group: tipifarnib vs BSC | 0.049 | 0.114 | 1.050 | (0.84-1.314) | .667 |
| Age: ≥ 75 vs < 75 | 0.252 | 0.116 | 1.287 | (1.025-1.616) | .030 |
| ECOG: 2 vs 0 and 1 | 0.832 | 0.131 | 2.298 | (1.778-2.97) | .000 |
| Unfavorable cytogenetics: yes vs no | 0.564 | 0.120 | 1.758 | (1.39-2.223) | .000 |
| AML with myelodysplasia vs AML without myelodysplasia | −0.089 | 0.124 | 0.915 | (0.718-1.166) | .473 |
| LDH U/L: > 1500 vs ≤ 1500 | 0.081 | 0.271 | 1.085 | (0.638-1.845) | .764 |
| WBC count: > 25 giga/L vs ≤ 25 giga/L | 0.214 | 0.172 | 1.239 | (0.884-1.736) | .213 |
| Bone marrow blasts: > 50% vs ≤ 50% | 0.542 | 0.124 | 1.719 | (1.347-2.194) | .000 |
Regression analysis of survival data (number of observations used = 362) was based on Cox proportional hazards model.